header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

PROSPECTIVE CONSECUTIVE MULTICENTRE STUDY OF 1030 ASRTM (DE PUY, WARSAW, IN) SURFACE HIP ARTHROPLASTIES.



Abstract

Introduction: Over 20,000 DePuy ASRTM hip resurfacing procedures have been performed since 2003, the implant design applying modern engineering and tribological principles to minimise metal-on-metal bearing wear. Enhanced fixation of both components, high-carbon cobalt-chromium alloy, reduced material thickness and small diametral clearance 100–150 microns are all supported by non-clinical testing. There are published reports of very low wear on hip joint simulators (Dowson D, et al. 2004 Dec;19(8 Suppl 3):124–30.), low wear on retrieval analysis (Morlock MM et al 1: Proc Inst Mech Eng [H]. 2006 Feb;220(2):333–44.) and excellent clinical results (Siebel T et al, Proc Inst Mech Eng [H]. 2006 Feb;220(2):345–53. We recently reported median whole blood chromium and cobalt ion levels of 1.56 ppb and 1.65 ppb at 24 months (Cobb AG et al, British Orthopaedic Association Congress 2007)

Methods: 1030 consecutive cases carried out by 3 of the surgeon-designers between July 2003 and May 2007 have been studied prospectively at annual intervals. 2 to 4 years follow-up data is available on 293 hips.

Results: There have been 11 revisions for fracture (1.06%), 6 in patients aged over 65 years(3.4%), 5 in patients aged up to 65 years (0.6%) (P< 0.001).

There have been 3 revisions for cup loosening (0.29%) and 3 for pain (0.29%). 5 patients have died (0.51%). There was one revision for infection and one for impingement.

Average Harris Hip Score rose from 57.0 to 97.1, and 60% of patients scored 100.

UCLA activity score was 6 or over in 91%, and the median score was 7.5.

All failures were evident by 12 months

The Cumulative Survival Rate at 3 years was 97.4%,, 99.5% for 55 years and under, 98.3% for under 65 years, and 94.2 % 65 years and over.

Discussion: The 2 to 4 year clinical follow-up of the latest generation of surface hip implants is satisfactory. Technical errors during implantation or patient selection accounted for most of the failures. The risk of failure between 12 months and 4 years is low.

Correspondence should be addressed to Mr Peter Howard, Editorial Secretary, BHS, c/o BOA, The Royal College of Surgeons, 35–43 Lincoln’s Inn Fields, London WC2A 3PE, England.